AlumisALMS -3.67%12 Debt-to-Equity is 0.06 as of Mar. 2026, which is 25% below its 10-year median of 0.08. GuruFocus rates ALMS with a GF Score™ of 12/100. The stock has 6 warning signs investors should review. Among 966 Biotechnology companies, Alumis ranks better than 68.43% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Alumis's Debt-to-Equity or its related term are showing as below:
ALMS'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.1 Med: 0.08 Max: 0.19
Current: 0.06
During the past 4 years, the highest Debt-to-Equity Ratio of Alumis was 0.19. The lowest was -0.10. And the median was 0.08.
ALMS's Debt-to-Equity is ranked better than 68.43% of 966
companies
in the Biotechnology industry
Industry Median: 0.16
vs ALMS: 0.06
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Alumis Debt-to-Equity Related Terms
Alumis Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Alumis's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALMS vs ARQT, QURE, DYN: Debt-to-Equity Comparison
For the Biotechnology subindustry, Alumis's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alumis Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alumis's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Alumis's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alumis (ALMS) has a Debt-to-Equity of 0.06 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Alumis and its competitors. This is 25% below median its historical median of 0.08. According to the industry distribution chart, Alumis ranks #305 out of 966 companies in the Biotechnology industry, placing it in the top 31.6%.
Is Alumis' Debt-to-Equity too high?
Alumis' current Debt-to-Equity of 0.06 is 25% below median its 10-year median of 0.08. The Biotechnology industry median Debt-to-Equity is 0.16. Alumis' value of 0.06 is 62.5% below this industry median. Based on the distribution chart, Alumis ranks #305 out of 966 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Alumis has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alumis' Debt-to-Equity compare to ARQT and QURE?
According to the Biotechnology industry distribution chart, Alumis ranks #305 out of 966 companies for Debt-to-Equity. This puts Alumis in the upper half of its industry. The industry median Debt-to-Equity is 0.16. Alumis' value of 0.06 is 62.5% below this benchmark. While the company's 10-year median is 0.08 vs. the industry median of 0.16, Alumis has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alumis's current Debt-to-Equity of 0.06 is 62.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Alumis and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alumis's current Debt-to-Equity is 0.06, which is 25% below median its own 10-year median of 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alumis stock overvalued right now?
Alumis (ALMS) has a current Debt-to-Equity of 0.06. The current Debt-to-Equity is 0.06, which is 25% below median its 10-year median of 0.08 and 62.5% below the Biotechnology industry median of 0.16. Alumis' overall GF Score™ is 12/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Alumis (ALMS), the current Debt-to-Equity is 0.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
12GF Score
Get the complete analysis for ALMS
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALMS has been successfully added to your 
